Introduction
============

Nitric oxide (NO) is an important mediator of diverse physiologic and pathologic processes, including arthritis \[[@B1],[@B2]\]. Joint inflammation in autoimmune MRL-*lpr*/*lpr*mice and rats with adjuvant-induced arthritis \[[@B3]-[@B9]\] is dependent on the enhanced production of NO. NO, a lipid- and water-soluble gas, is ideally suited as a potent inflammatory mediator because of its strong reactivity with oxygen, superoxide, and iron-containing compounds. This inherent reactivity of NO translates into a relatively short half-life (for example 1 to 10 s), which has made it technically difficult to quantify in solution. Instead of directly measuring NO, investigators have estimated NO production by measuring levels of nitrate (NO~3~^-^) and nitrite (NO~2~^-^), stable anions derived from the reaction of NO with superoxide. In general, serum levels and urinary excretion of nitrite + nitrate (NOx) reflect the total production of NO by the body \[[@B10],[@B11]\]. Care must be taken in the interpretation of results from these studies, because ingested nitrite or nitrate and renal insufficiency elevate both serum and urine nitrate as well as nitrite \[[@B10],[@B12],[@B13]\].

Although previous work has provided evidence in rheumatoid arthritis (RA) for increased production of systemic NO \[[@B14]-[@B21]\] and increased expression of inducible NO synthase (NOS2) and production of NO \[[@B22]\], most studies of urine and serum NOx levels have been performed in patients eating a normal diet \[[@B17]\] or after only an overnight fast \[[@B15]\]. Other approaches that assess NO production are less subject to dietary influences. For example, nitrotyrosines, which are formed from the reaction of peroxynitrite (a product of NO and superoxide) with tyrosine, can be measured by immunoassay or high-performance liquid chromatography \[[@B16],[@B23]\]. Using this method, Kaur and Halliwell \[[@B16]\] have detected nitrotyrosines in serum and synovial fluid from patients with active RA, but not in serum from controls.

In the present study, we assessed NO production *in vivo*by measuring levels of NOx in urine, serum, and saliva in patients with active RA and in normal subjects under conditions of strict dietary NOx restriction. In a comparison between patients with RA and normal subjects, we found that patients with RA had comparable levels of NOx in urine and saliva, elevated serum NOx and serum NOx/creatinine, normal renal creatinine clearance, and reduced renal NOx clearance and fractional excretion. The reduced renal NOx clearance and fractional excretion limit the use of serum NOx and urine NOx excretion as parameters of NO production in patients with RA and their potential as disease markers.

Materials and methods
=====================

Patients and controls
---------------------

Twenty-five patients who met the American College of Rheumatology 1987 revised criteria \[[@B24]\] for the classification of RA were recruited from the Duke University Medical Center (DUMC) Rheumatology Outpatient Clinics. The patients were taking stable doses of prednisone (not more than 10 mg/day) and nonsteroidal anti-inflammatory drugs (NSAIDs) for at least 2 weeks before study entry. If they were taking second-line drugs, such as methotrexate, hydroxychloroquine, gold, sulfasalazine, or azathioprine, doses of these medications were stable for at least 4 weeks before study entry. No subjects were taking anti-cytokine agents such as anti-TNF antibody, a treatment that we have shown decreases the overexpression of blood mononuclear cell NOS2 in RA \[[@B25]\]. For comparison, 20 age-matched (within 5 years) and gender-matched subjects without RA were recruited by newspaper advertisement. Patients and controls who had coexisting chronic inflammatory conditions, active infections, malignancy, cirrhosis, or a serum creatinine level of more than 2.5 mg/dl were excluded from participation. Patients were not allowed nitrate-containing medications or permitted to smoke during the study period. The DUMC Institutional Review Board approved the protocol, and informed consent was obtained from each subject before participation. These are the same patient and control subjects as those reported previously in whom we showed greater NOS2 expression and *in vitro*NO production in the patients with RA than in controls \[[@B22]\].

Study design
------------

Eligible subjects were hospitalized for 3 days on the inpatient unit of the General Clinical Research Center at DUMC. Subjects had a complete history and physical examination at baseline to confirm eligibility. In addition, the patients with RA were comprehensively evaluated for disease activity with the use of the following measures:

1\. Tender and swollen joint count (maximum of 68 tender and 66 swollen joints).

2\. Duration of morning stiffness.

3\. Patient assessment of pain on a 10 cm visual analog scale.

4\. Physician global assessment of disease activity with the use of a 10 cm analog scale.

5\. Functional capacity determined with the modified Stanford Health Assessment Questionnaire (mHAQ) \[[@B26]\].

The functional class was determined with the American College of Rheumatology 1991 revised criteria for the classification of global functional status \[[@B27]\]. Rheumatologic assessments and routine laboratory studies were performed at baseline and on day 3. Because no significant differences in disease measures were found between baseline and day 3, the disease-related parameters at baseline were used in the analysis below.

The characteristics of the patients with RA and the healthy controls have been published previously \[[@B22]\]. The two groups were similar with respect to median age (patients with RA, 58 years; controls, 56 years) and gender (patients with RA, 17 women and 8 men; controls, 14 women and 6 men). The median duration of disease for the patients with RA was 9 years. In general, the patients with RA had severe disease, as reflected by the high proportion of patients with subcutaneous nodules (48%), the high proportion of patients currently taking a second-line drug (72%), and the frequent past use of second-line drugs (72%). Disease activity in the RA group was characterized by high median tender (31) and swollen (28) joint counts, prolonged morning stiffness (median duration 60 minutes), a median erythrocyte sedimentation rate of 26 mm/hour, a median CRP of 13 mg/l, and moderate functional disability (median mHAQ score 1.62). No control subjects were taking prednisone, and only two controls were taking a NSAID at the time of the study.

Dietary intervention
--------------------

The subjects were fed a low-NOx diet that met the recommended allowances for weight maintenance in kilocalories, carbohydrate, fat, and protein. Two caloric diets were available for selection by subjects: first, a 2,000 kcal diet of 18% protein, 60% carbohydrates, and 22% fat, yielding about 100 μmoles of NOx per day; and second, a 2,500 kcal diet of 19% protein, 60% carbohydrates, and 21% fat, yielding about 110 μmoles of NOx per day. The amount of NOx in these diets was determined as described previously \[[@B28]\]. The diet allowed unlimited consumption of distilled water. A research dietician obtained a dietary history from each subject at the time of admission to estimate the oral intake of NOx during the previous 24 hours and also monitored the daily oral intake of food and beverages in the hospital to estimate the daily consumption of NOx.

Blood, urine, and saliva collection, and NOx assays
---------------------------------------------------

Blood samples were drawn by venipuncture from subjects at 0, 24, 48, and 72 hours for determination of serum creatinine and NOx concentrations. NO reacts with oxygen to form nitrite and nitrate. We used the Griess reagent to measure nitrite \[[@B29],[@B30]\]. We first converted all nitrate to nitrite with bacterial nitrate reductase, and then this nitrite (representing total nitrite plus nitrate \[NOx\]) was measured with the Griess reagent. Propan-2-ol (\'isopropanol\') was added to urine collected during a 24 hour period at a ratio of 1:10 (propan-2-ol/urine) to prevent bacterial growth, because contaminating bacterial enzymes can introduce errors. Urine and saliva were used unprocessed, but serum samples were filtered with Centricon filters (Amicon, Beverly, MA, USA) before performing the NOx assays. We incubated 50 μl of sample for 30 minutes with 7 μl of 1 M Tris pH 7.5, 10 μl of 0.02 mM NADPH, 20 μl of 5 mM glucose 6-phosphate (G6P), 3 μl of 10 units/ml glucose-6-phosphate dehydrogenase (G6PD), and 10 μl of a 10 unit/mL solution of nitrate reductase at room temperature (20 to 23°C). The G6P and G6PD were used to eliminate excess NADPH, which might interfere with the overall Griess reaction. We incubated 75 μl of this mixture for 10 minutes with 75 μl of Griess reagent I (3% sulfanilamide in 2.5% phosphoric acid) and Griess reagent II (0.3% naphthylethylenediamine in 2.5% phosphoric acid) at room temperature. The absorbances at 550 nm were measured, and concentrations of NOx were determined by comparison with a standard curve generated with reagent nitrate.

Twenty-four-hour urine samples were collected on day 1 (0 to 24 hours), day 2 (24 to 48 hours), and day 3 (48 to 72 hours) to quantify urinary excretion of NOx. Urine volume and creatinine content were measured for each 24-hour sample to calculate creatinine and NOx clearances. The renal clearance of NOx was calculated by the following formula: clearance = (Urine flow rate (liters/24 hours) × Urine NOx (mol/l))/(Serum NOx (mol/l)). Renal fractional excretion of NOx was determined by dividing the renal NOx clearance by the creatinine clearance. Saliva specimens were obtained after 72 hours for measurement of basal and stimulated salivary NO production with the use of a method described previously \[[@B31]\]. Subjects first rinsed their mouth with an antiseptic (Peridex) to reduce bacterial contamination. For basal measurements, 0.2 to 0.3 ml of saliva was collected within 1 minute of the antiseptic rinse. For measurement of stimulated flow, subjects rinsed their mouth with 1 ml of lemon juice followed by a second rinse with distilled water. Samples (0.2 to 0.3 ml) were collected at 0 to 1 minute and at 5 to 6 minutes. The Schirmer\'s tear test was done without anesthesia as noted previously \[[@B32]\].

Analyses
--------

Descriptive statistics were expressed in terms of the median and interquartile range for continuous variables. Comparisons between cases and controls regarding various parameters of NOx, NOS, and disease measures were made using the Wilcoxon rank sum test. The comparisons of renal clearance and fractional excretion of NOx between cases and controls in each of the three 24-hour time periods used only the 23 RA patients and 17 controls for whom assay results were available for the first two time periods. For the 8 RA patients with missing observations for the third 24-hour period, it was conservatively assumed that their NOx clearance and fractional excretion on day 3 were the same as that on day 2 since the 15 other RA patients all had lower values on day 3 for both of these measures. The relationship of urinary NOx to disease measures was determined using a Spearman correlation coefficient.

Results
=======

Dietary intake of NOx
---------------------

The subjects were hospitalized and placed on a NOx-restricted diet to minimize exogenous sources of these constituents. The pre-study dietary content of NOx was highly variable between individuals (Table [1](#T1){ref-type="table"}), but normal subjects were not significantly different from patients with RA. Once individuals had been placed on the restricted diet, we confirmed by careful history and inspection of food trays that they had consumed only the minimal amounts of NOx allowed by the diet. Although control subjects on days 2 and 3 ingested slightly more NOx than RA subjects did, these differences were very small in comparison with the measured levels of these compounds in the serum and urine.

Urine and serum NOx levels
--------------------------

In conditions of low ingestion of exogenous NOx and normal function, urinary NOx excretion reflects total production of NO by the body \[[@B10],[@B33]\]. On the basis of other studies \[[@B10],[@B12],[@B33]\], we predicted that our dietary intervention would quickly decrease urinary NOx excretion, which would then stabilize after about 24 to 48 hours. This prediction was confirmed in healthy controls and patients with RA, whose urinary NOx excretions decreased by 21 to 30% over the 72-hour interval (Figure [1](#F1){ref-type="fig"}). The differences at each period of urine collection were not different when comparing normal controls with patients with RA (*p*\> 0.05). Serum NOx levels decreased to an even greater degree with dietary NOx restriction (as much as 42% decrease) and stabilized over 72 hours (Figure [2](#F2){ref-type="fig"}). Despite an absence of increased urinary NOx excretion in patients with RA, patients with RA had significantly higher serum NOx levels at all time points (Figure [2](#F2){ref-type="fig"}). Likewise, day 3 serum NOx/creatinine ratios were significantly higher in patients with RA than in controls, whereas urinary NOx/creatinine ratios were not significantly different between these two groups (Figure [3](#F3){ref-type="fig"}). The use of NOx/creatinine ratios acts as a control for individual differences in creatinine clearances. The finding of increased NOx and NOx/creatinine ratios in serum (but not in urine) in patients with RA raised the possibility that controls and subjects with RA might differ in their renal elimination of NOx.

Renal clearance and fractional excretion of NOx
-----------------------------------------------

The creatinine clearance was slightly higher in patients with RA, but this difference was not statistically significant (Table [2](#T2){ref-type="table"}). This finding indicates that a reduction in glomerular filtration rate in patients with RA was not a likely explanation for any elevated serum and urine NOx levels in RA. However, the renal clearance and fractional excretion of NOx were significantly lower in subjects with RA than in controls at all time points. There was day-to-day variability in the renal clearance of NOx, with lower clearances at late time points as the NOx-restricted diet diminished the total NOx load.

We performed a subgroup analysis of the patients with RA to investigate whether certain medications might be associated with altered renal clearance of NOx. The median urinary NOx clearance was higher in NSAID users (*n*= 13) than in non-users (*n*= 12) (49.8 ml/min versus 23.9 ml/min, respectively; *p*= 0.017). There were no significant differences in urinary NOx clearance between prednisone users (*n*= 16) and non-users (*n*= 9) (38.7 ml/min versus 53.1 ml/min, respectively) and methotrexate users and non-users (33.8 ml/min versus 40.9 ml/min, respectively). Our data indicate that anti-rheumatic medications were not likely to be responsible for the lower renal clearance of NOx in the patients with RA. However, it is possible that an analysis of larger numbers of subjects might show differences.

Saliva and tears
----------------

Saliva can contain large amounts of NO catabolites \[[@B13],[@B34]\]. Dietary nitrate is converted to nitrite in saliva, is swallowed, and then may appear as nitrate or nitrite in saliva (the enterosalivary circulation), with salivary NOx sometimes reaching millimolar concentrations \[[@B13],[@B34]\]. Salivary flow is regulated in part by NO \[[@B31]\]. The prevalence of sicca symptoms in RA ranges from 25% to 65% \[[@B35]-[@B39]\]. We examined basal and stimulated salivary flow and basal tear flow (Schirmer\'s tear test), and we measured NOx levels in saliva (Table [3](#T3){ref-type="table"}). Unstimulated and stimulated salivary flow rates were significantly lower in subjects with RA than in controls. Similarly, Schirmer\'s tear test demonstrated that patients with RA had a lower tear flow than healthy subjects. We did not measure NOx levels in tears. Basal and stimulated salivary NOx levels were not different between normal controls and patients with RA (Table [3](#T3){ref-type="table"}).

Relationship of NO parameters to disease activity
-------------------------------------------------

In an earlier report of studies involving these subjects, we showed that the NOS activity of freshly isolated peripheral blood mononuclear cells (PBMCs) was significantly higher in subjects with RA and that PBMCs produced more NOx *in vitro*in the basal state and after stimulation with IFN-γ \[[@B22]\]. Furthermore, NOS activity correlated significantly with the number of swollen and tender joints. We had postulated that other measures of NO production (serum NOx, urine NOx, serum NOx/creatinine ratios, urine NOx/creatinine ratios) would correlate with certain disease activity measures. We therefore assessed the relationships of the serum NOx levels at 72 hours, the urine NOx excretion during the period from 48 to 72 hours, the serum and urine NOx/creatinine ratios during the period from 48 to 72 hours, and NOx urinary clearance and fractional excretion during the period from 48 to 72 hours, relative to 10 RA activity parameters (erythrocyte sedimentation rate, serum C-reactive protein, hemoglobin concentration, duration of morning stiffness, physician assessment of pain (visual analog scale), patient pain self-assessment (visual analog scale), patient self-assessment of disease severity (visual analog scale), number of tender joints, number of swollen joints, and functional disability (mHAQ)). Results showed a significant correlation of the serum NOx/creatinine ratio with the number of painful joints (*r*= 0.59; *p*= 0.012), physician assessment of pain (*r*= 0.40; *p*= 0.015), and hemoglobin concentration (*r*= 0.36; *p*= 0.030). The urine NOx/creatinine ratio was significantly correlated with the mHAQ (*r*= 0.40; *p*= 0.047). After corrections for multiple comparisons, none of these remained significant. Urine NOx clearance and fractional excretion did not correlate significantly with any of the parameters. We conclude that (despite our carefully limiting the dietary intake of nitrates and nitrites) serum and urinary measures of NO production are of limited usefulness as biomarkers of disease activity in RA. It is possible that stronger correlations might be found by analyzing larger numbers of subjects.

Discussion
==========

NO is synthesized from L-arginine by a family of enzymes known as nitric oxide synthases. These enzymes are encoded by three separate genes and are NOS1 (neural NOS), NOS2 (inducible NOS), and NOS3 (endothelial NOS). NOS1 and NOS3 are calcium-dependent and generally produce low levels of NO involved in normal physiologic processes. In contrast, NOS type 2 is calcium-independent. Its expression is upregulated by IFNα, IFNγ, IL-1, and TNF-α as well as other pro-inflammatory mediators, resulting in sustained and high-level NO output \[[@B40],[@B41]\].

Several lines of evidence implicate NO in the pathogenesis of joint inflammation. Rodents in animal models of arthritis generate abundant quantities of NO, as reflected in high levels of serum and urinary NOx that develop in association with disease manifestations \[[@B3]-[@B6],[@B42]\]. Treatment of these animals with NOS inhibitors or NO quenchers suppresses NO production and effectively abrogates joint inflammation. These findings have prompted studies in humans to determine whether patients with RA, like the rodents with arthritis, also have heightened NO production. Some investigators have analyzed NO production and NOS in human synovial tissue. For example, Sakurai and colleagues \[[@B43]\] showed that macrophages and endothelial cells from synovial tissue of patients with RA express NOS2 mRNA and protein, and generate NO *in vitro*. We also noted that circulating mononuclear cells from patients with RA are activated to express NOS type 2 and overproduce NO \[[@B22]\].

Other approaches have focused on systemic NO production. In one study, Grabowski and colleagues \[[@B15]\] showed that patients with RA have threefold higher urinary nitrate/creatinine ratios than controls, implying that urinary NOx can be used in this clinical setting as a reliable index of excessive NO production. Farrell and colleagues found that patients with RA or osteoarthritis (OA) had higher serum nitrite (not nitrite + nitrate) levels than normal controls (with RA being higher than OA) \[[@B17]\]. Similarly, Euki and colleagues found that serum nitrite was higher in patients with RA than in normal controls and patients with OA, and that nitrite levels were correlated with clinical parameters of RA activity, C-reactive protein, serum TNF, and serum IL-6 \[[@B14]\]. These workers did not control NOx intake \[[@B14],[@B17]\]. Onur and colleagues showed that patients with RA had higher serum NOx levels than controls, and that NOx was correlated significantly with C-reactive protein and clinical disease activity \[[@B18]\]. The subjects were told to avoid foods high in nitrate for 3 days before blood samples were taken, and were asked to fast overnight before sampling blood \[[@B18]\]. Pham and colleagues showed that patients with RA had significantly higher serum NOx levels than normal control individuals and patients with OA \[[@B19]\].

The investigations of Onur and colleagues and Pham and colleagues did not correct for renal function. Choi noted higher serum NOx levels in patients with RA than in healthy individuals, but he found no correlation of serum NOx with disease activity measures \[[@B20]\]. In his studies, subjects were fasted for only 12 hours, and there was no correction for renal function. Ersoy and colleagues noted that patients with RA had higher serum NOx levels than normal controls, and that NOx levels were significantly correlated with disease activity \[[@B21]\]. These investigators did not control NOx intake or correct for renal function. Studies with stable isotopic (non-radioactive) L-arginine can be useful in the evaluation of NO formation *in vivo*in humans \[[@B44]\]. However, renal function abnormalities can result in difficulties in the interpreting results, because serum and urine nitrate and nitrite containing the isotope label are the measured products.

Our study of patients with RA with normal renal creatinine clearance illustrates that serum NOx and urine NOx excretion levels may be difficult to use as measures of whole-body NO production, even when one carefully controls NOx ingestion. We found under conditions of stringent dietary control that urinary NOx levels are no higher in patients with RA than in controls. NO in the presence of superoxide can produce peroxynitrite, which in turn can nitrate the phenolic group of amino acids (especially tyrosine) \[[@B23]\]. Nitrotyrosines were not assessed in the present study, but others have previously detected nitrotyrosine in serum of patients with active RA \[[@B16]\]. Although NO incorporated into nitrotyrosines may represent a source of unmeasured NO catabolite, it is unlikely to be more than 10% of the total NO formed in the body \[[@B45]\].

Urinary NOx has been generally accepted as a measure of total body NO production \[[@B10],[@B12],[@B46]-[@B49]\]. The proportion of NOx excreted in the urine constitutes 50 to 60% of the total body clearance of these compounds, with the remaining amounts being eliminated in unknown proportions by the exocrine glands and by the respiratory and gastrointestinal tracts \[[@B11],[@B12]\]. The total amount of NOx measured in the urine and serum derives from both endogenous and exogenous sources. As shown in our study, individuals vary substantially in their dietary intake of nitrate and nitrite. Unless individual variability of NOx intake is taken into account, measures of NOx in urine and serum will probably not reflect endogenous NO production, and exogenous NOx might obscure true differences in endogenous NOx production. Grabowski and colleagues \[[@B15]\] found in healthy volunteers that urinary NOx levels after an overnight fast are not significantly altered by dietary intake of nitrate and nitrite. Our results demonstrate a significant decrease in NOx in urine and serum after 24 hours of a NOx-restricted diet. However, we do not demonstrate a significant difference in NOx in urine between normal subjects and patients with RA. This finding suggests that the patients with RA may have differed from control subjects in the renal elimination of NOx. Grabowski and colleagues \[[@B15]\] noted a higher average urinary nitrate/creatinine ratio in patients with RA than in controls after only an overnight fast. Our analyses showed that urinary NOx and NOx/creatinine levels after 1, 2, or 3 days of a NOx-restricted diet were not different between normal and RA subjects, but serum NOx/creatinine levels were significantly higher in our study in patients with RA. However, this difference is difficult to interpret in view of the finding that patients with RA have a decrease in renal NOx clearance.

Nitrite and nitrate are each filtered by the kidney and reabsorbed in the proximal tubule, but there may be other sites of tubular reabsorption and secretion \[[@B50]\]. Altered renal NOx clearance has not previously been described in humans except in cases with substantial reductions of glomerular filtration \[[@B51]\]. In the present study, the RA and control groups had similar creatinine clearances, and none of the subjects had a serum creatinine above 2 mg/dl. Thus, differences in glomerular filtration do not seem to explain the lower NOx clearances in the RA group. Moreover, treatment with NSAIDs, prednisone, or methotrexate was not associated with a lower NOx clearance, pointing away from concomitant anti-rheumatic therapy as the cause of the reduced NOx clearance. This analysis must be interpreted with caution in view of the small numbers of subjects in each of the medication subgroups and the fact that many of the patients were taking multiple anti-rheumatic agents. We suspect that the altered renal clearances and fractional excretions of NOx in patients with RA are due to intrinsic renal tubular abnormalities. Renal tubular abnormalities have been described in patients with RA and in those with Sjögren\'s syndrome \[[@B52],[@B53]\].

Exocrine dysfunction of the lacrimal and salivary glands may occur in RA, leading in some cases to secondary Sjögren\'s syndrome \[[@B35]-[@B39]\]. Thus, alterations in NOx excretion (and possibly NOx clearance comparable to those we note in the kidney) by the salivary glands might influence NOx levels in serum and urine. Our studies document low basal salivary flow and tear flow in patients with RA, but salivary NOx levels after 3 days of a low NOx diet were comparable in controls and in subjects with RA. Although salivary flow can be influenced by NO \[[@B31]\], we find no evidence that this is disordered in RA. We did not measure NOx clearance by the salivary glands. We speculate that salivary gland epithelium, like renal tubular cell function, which we showed here has an altered NOx clearance in RA, may also have diminished NOx clearance. This could modify the excretion of NOx into saliva and partly contribute to the elevated serum NOx in RA.

Our earlier report of studies of these subjects showed that NOS activity of freshly isolated PBMCs was significantly higher in subjects with RA and that isolated PBMCs produced more NOx *in vitro*in the basal state and after stimulation with IFN-γ. In addition, NOS activity was significantly correlated with the number of swollen and tender joints \[[@B22]\]. Although NOx is much easier to measure than NOS activity, our results emphasize the limitations of using serum and urine NOx levels as indices of NOS activity and NO production in patients with RA. We have shown how dietary influences and altered urinary NOx clearances make it difficult to interpret serum and urine NOx levels. Future studies of NO production in RA are therefore likely to be more informative if they focus on specific anatomic or cellular compartments relevant to the pathophysiology of disease.

Conclusion
==========

Subjects with RA may have altered renal clearance and fractional excretion of NOx. This complicates the interpretation of measures of serum NOx concentrations and urine NOx levels, even when one carefully controls NOx ingestion. NOx measures as parameters of RA activity must be used with caution. Studies of NO production in RA are likely to be more informative if they focus on specific anatomic or cellular compartments relevant to the pathophysiology of disease.
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Figures and Tables
==================

![Urinary excretion of NOx. Consecutive 24-hour urine samples were collected from 25 patients with active rheumatoid arthritis (RA) and 20 healthy controls (N) who were receiving a diet low in nitrate and nitrite. During each of the time periods, no statistically significant differences were observed between the two groups in 24-hour urinary excretion of NOx. Values are expressed as medians (horizontal lines), means (filled circles), interquartile ranges (boxes), and 10th to 90th centile ranges (whiskers). NOx, NO~2~^-^(nitrite) + NO~3~^-^(nitrate).](ar2030-1){#F1}

![Serum concentration of NOx. Serum was obtained from 25 patients with active rheumatoid arthritis (RA) and 20 healthy controls (N) at 0, 24, 48, and 72 hours after the initiation of a diet low in nitrate and nitrite. Serum NOx concentrations were higher in the RA group than in the control group at 0, 24, 48, and 72 hours (*p*= 0.028, 0.0004, 0.046, and 0.053, respectively). Values are expressed as medians (horizontal lines), means (filled circles), interquartile ranges (boxes), and 10th to 90th centile ranges (whiskers). NOx, NO~2~^-^(nitrite) + NO~3~^-^(nitrate).](ar2030-2){#F2}

![NOx/creatinine ratios in urine and serum. Urine and serum samples from 25 patients with active rheumatoid arthritis (RA) and 20 healthy controls (N) were analyzed 72 hours after initiation of a diet low in nitrate and nitrite. NOx/creatinine ratios were calculated and plotted. The difference in serum NOx/creatinine values between the RA and control groups was statistically significant (*p*= 0.013). The difference between control and RA subjects for urine NOx/creatinine was not statistically significant. NOx, NO~2~^-^(nitrite) + NO~3~^-^(nitrate).](ar2030-3){#F3}

###### 

Oral NOx intake before admission and during ingestion of the nitrate- and nitrite-restricted diet

  Period                      Group    *n*   Median NOx intake (μmol) (interquartile range)   *p*
  --------------------------- -------- ----- ------------------------------------------------ -----
  Before admission            Normal   20    1,875 (94--13,900)                               NS
                              RA       25    957 (101--5,162)                                 
  Hospital day 1 (0--24 h)    Normal   20    111 (98--139)                                    
                              RA       25    98 (54--150)                                     
  Hospital day 2 (24--48 h)   Normal   20    126 (98--140)                                    
                              RA       25    123 (89--140)                                    
  Hospital day 3 (48--72 h)   Normal   20    126 (112--140)                                   
                              RA       25    119 (76--140)                                    

NOx, nitrite + nitrate; NS, not significant (comparing normal and RA); RA, rheumatoid arthritis.

###### 

Renal clearance of creatinine and NOx, and fractional excretion of NOx

  Measure                              Group    *n*   Median (interquartile range)   *p*
  ------------------------------------ -------- ----- ------------------------------ ------------
  Creatinine clearance (ml/min)        Normal   20    84 (74--97)                    NS (0.071)
                                       RA       25    99 (82--133)                   
  NOx clearance (ml/min), 0--24 h      Normal   17    125(72--209)                   0.004
                                       RA       23    31 (16--73)                    
  NOx clearance (ml/min), 24--48 h     Normal   17    69 (38--106)                   0.026
                                       RA       23    38 (20--58)                    
  NOx clearance (ml/min), 48--72 h     Normal   17    47 (20--80)                    0.014
                                       RA       23    27 (11--34)                    
  NOx fractional excretion, 0--24 h    Normal   17    1.40 (0.78--2.26)              0.004
                                       RA       23    0.35 (0.19--0.82)              
  NOx fractional excretion, 24--48 h   Normal   17    0.81 (0.48--1.23)              0.010
                                       RA)      23    0.29 (0.17--0.71)              
  NOx fractional excretion, 48--72 h   Normal   17    0.56 (0.16--0.94)              0.010
                                       RA       23    0.28 (0.11--0.38)              

NOx, nitrite + nitrate; NS, not significant (comparing normal and RA); RA, rheumatoid arthritis.

###### 

Saliva and lacrimal measures

  Measure                                     Group    *n*   Median (interquartile range)   *p*^a^
  ------------------------------------------- -------- ----- ------------------------------ --------
  Unstimulated salivary flow (ml/min)         Normal   20    5.5 (4.0--9.5)                 0.0009
                                              RA       25    3.0 (1.0--5.0)                 
  Stimulated salivary flow, 15 min (ml/min)   Normal   20    8.0 (3.8--10.5)                0.0005
                                              RA       25    4.0 (1.5--4.5)                 
  Basal salivary NOx (μM)^b^                  Normal   20    46.1 (19.5--71.3)              NS
                                              RA       25    48.8 (31.3--83.4)              
  Stimulated salivary NOx, 15 min (μM)^b^     Normal   20    48.1 (26.6--98.7)              NS
                                              RA       25    37.0 (15.7--81.9)              
  Schirmer\'s tear test, left (mm)            Normal   19    14.0 (5.0--30.0)               0.025
                                              RA       25    8.0 (2.0--17.5)                
  Schirmer\'s tear test, right (mm)           Normal   19    12.0 (5.0--30.0)               0.008
                                              RA       25    5.0 (1.5--10.0)                

NOx, nitrite + nitrate; ^a^NS\*, not significant; RA, rheumatoid arthritis. ^a^Comparing normal and RA; ^b^saliva collected on the third day of the diet.
